|Articles|July 1, 1999

Community-Acquired Pneumonia: Achieving Optimal Outcomes in Antimicrobial Therapy
Volume 5
Issue 9 Suppl

Introduction

Author(s)Pamela Benson-Sardo, RPh

Download PDF: Introduction

Articles in this issue

almost 27 years ago

Article

Participating Faculty

almost 27 years ago

Article

Community-Acquired Pneumonia: Incidence, Epidemiology, and Current Therapeutic Management

almost 27 years ago

Article

An Overview of Integrated Managed Care

almost 27 years ago

Article

Community-Acquired Pneumonia: Approaches within Managed Care

almost 27 years ago

Article

Antibiotic Therapy in Community-Acquired Pneumonia and the Role of the Hospital Pharmacist

almost 27 years ago

Article

Selected Abstracts

almost 27 years ago

Article

Bibliography

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Introduction

Articles in this issue

Related Content

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Trending on AJMC

GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale

What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO

ACA Enrollment Erosion Deepens After Open Enrollment Ends

Efgartigimod Effective in Broad Subsets of Patients With gMG

Alopecia Areata Takes a Hidden Toll on Work, Relationships, and Self-Care